Page last updated: 2024-12-07

argipressin, deaminopenicillamine(1)-o-methyl-tyr(2)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

argipressin, deaminopenicillamine(1)-O-methyl-Tyr(2)-: vasopressin antagonist; RN refers to (L-Tyr-L-Arg)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119517
MeSH IDM0092587

Synonyms (18)

Synonym
gtpl2225
d[pen1,tyr(me)2]avp
n-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-methoxyphenyl)methyl]-20,20-dimethyl-6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-5,8,11,14,17-pentazacycloicosan
[deamino-pen1, o-me-tyr2, arg8]-vasopressin, >=97% (hplc)
vasopressin, 1-(3-mercapto-3-methylbutanoic acid)-2-(o-methyl-l-tyrosine)-8-l-arginine-
vasopressin, deaminopenicillamin(1)-o-methyltyr(2)-
1-deaminopenicillamine-2-(o-methyl-tyr)-argipressin
argipressin, deaminopenicillamine(1)-o-methyl-tyr(2)-
arginine vasopressin, deaminopenicillamine(1)-o-methyl-tyr(2)-
dpmetyravp
argipressin, deaminopenicillamine(1)-o-methyltyrosine(2)-
deaminopenicillamine-2-(o-methyl-tyr)vasopressin
dptyr(me)avp
67269-08-3
n-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-methoxyphenyl)methyl]-20,20-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-car
(deamino-pen1,tyr(me)2,arg8)-vasopressin
Q27077108
vasopressin, 1-(3-mercapto-3-methylbutanoicacid)-2-(o-methyl-l-tyrosine)-8-l-arginine-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves were established for AVP and flank marking in the presence or absence of different concentrations of each antagonist."( Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists.
Albers, HE; Ferris, CF; Meenan, DM; Singer, EA, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000Kidney international, Oct, Volume: 58, Issue:4
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (52.00)18.7374
1990's19 (38.00)18.2507
2000's4 (8.00)29.6817
2010's1 (2.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.10 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]